Open an account

Maze Therapeutics

MAZE · NASDAQ

$32.45+$2.75 (+9.26%)TodayMarket closed ·
Prev close $29.70

About MAZE

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM diseases. The company is headquartered in South San Francisco, California and currently employs 141 full-time employees. The company went IPO on 2025-01-31. The firm is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.

Employees
141
Headquarters
South San Francisco, California
Listed
Jan 31, 2025
Sector
Health Care
Industry
Pharmaceuticals
Website
mazetx.com

MAZE key statistics

Market cap
1.65B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
968.23K
Volume
1.57M
Open price
$29.82
High today
$32.61
Low today
$29.58
52 Week high
$53.65
52 Week low
$21.95

Maze Therapeutics (MAZE) at a glance

Maze Therapeutics (MAZE) last traded at $32.45, with a market cap of 1.65B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $29.58 and $32.61. The current price is 9.7% above the day's low and 0.5% below its high.

Volume so far is 1.57M shares, above the average of 968.23K shares a day.

Over the past year Maze Therapeutics has ranged from $21.95 to $53.65, and now sits 33% of the way up that range.

Maze Therapeutics met or beat analyst EPS estimates in 4 of the last 7 quarters. In Q2 FY26 it reported -$0.76 per share against an estimate of -$0.7487.

The average analyst price target is $63.52, 95.7% above the current price, from 10 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 10 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 14 analystsAvg $63.52
Low
$46.46
Now
$32.45
High
$115.50

MAZE earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 7 quarters, by 12.6% on average.

  1. Q4 FY24: reported -$18.32 per share against an estimate of $0.459
  2. Q1 FY25: reported -$1.15 per share against an estimate of -$0.7684
  3. Q2 FY25: reported -$0.77 per share against an estimate of -$0.8731
  4. Q3 FY25: reported -$0.66 per share against an estimate of -$0.7227
  5. Q4 FY25: reported -$0.65 per share against an estimate of -$0.7279
  6. Q1 FY26: reported -$0.45 per share against an estimate of -$0.5565
  7. Q2 FY26: reported -$0.76 per share against an estimate of -$0.7487

MAZE news

  • Avi Kapoor

    Crude Oil Moves Lower; Cintas Raises FY2026 Forecast

  • Avi Kapoor

    Dow Surges Over 300 Points; Chewy Shares Jump On Upbeat Earnings

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Press releasePRNewswire

    Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight

  • Press releaseGlobe Newswire

    Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

  • Vandana Singh

    Maze Shares Jump As Investors Bet Big On Experimental Treatment's Potential

  • Avi Kapoor

    Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Similar companies

Companies in the same industry as Maze Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.